Key result
Treatment with either riociguat or sildenafil prevented the deterioration of RV function and progression of pressure overload-induced right ventricular failure in mice.
Why the study?
Does sildenafil or riociguat improve right ventricular function and remodeling in a mouse model of pressure overload-induced right ventricular failure?
Does sildenafil or riociguat improve right ventricular function and remodeling in a mouse model of pressure overload-induced right ventricular failure?
Answers are grounded in this paper and cite their sources.
In a mouse model of pressure overload-induced right ventricular failure, both sildenafil and riociguat prevented RV functional deterioration, suggesting potential therapeutic approaches for PAH-associated RV failure.
Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by remodeling of the pulmonary vasculature and a rise in right ventricular (RV) afterload. The increased RV afterload leads to right ventricular failure (RVF) which is the reason for the high morbidity and mortality in PAH patients. The objective was to evaluate the therapeutic efficacy and antiremodeling potential of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil and the soluble guanylate cyclase stimulator riociguat in a model of pressure overload RV hypertrophy induced by pulmonary artery banding (PAB). Mice subjected to PAB, one week after surgery, were treated with either sildenafil (100 mg/kg/d, n=5), riociguat (30 mg/kg/d, n=5), or vehicle (n=5) for 14 days. RV function and remodeling were assessed by right heart catheterization, magnetic resonance imaging (MRI), and histomorphometry. Both sildenafil and riociguat prevented the deterioration of RV function, as determined by a decrease in RV dilation and restoration of the RV ejection fraction (EF). Although both compounds did not decrease right heart mass and cellular hypertrophy, riociguat prevented RV fibrosis induced by PAB. Both compounds diminished TGF-beta1 induced collagen synthesis of RV cardiac fibroblasts in vitro . Treatment with either riociguat or sildenafil prevented the progression of pressure overload-induced RVF, representing a novel therapeutic approach.
No takes yet. Share an insight, caveat, or question.
Rai et al. (2018) studied Pressure overload right ventricular hypertrophy / Pulmonary arterial hypertension (n=15). Sildenafil and Riociguat vs. Vehicle was evaluated on RV function and remodeling assessed by right heart catheterization, MRI, and histomorphometry. Treatment with either riociguat or sildenafil prevented the deterioration of RV function and progression of pressure overload-induced right ventricular failure in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: